Bastian Dehmel

2.6k total citations · 1 hit paper
40 papers, 1.8k citations indexed

About

Bastian Dehmel is a scholar working on Nephrology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bastian Dehmel has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Nephrology, 11 papers in Pathology and Forensic Medicine and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bastian Dehmel's work include Parathyroid Disorders and Treatments (26 papers), Dialysis and Renal Disease Management (14 papers) and Vitamin D Research Studies (8 papers). Bastian Dehmel is often cited by papers focused on Parathyroid Disorders and Treatments (26 papers), Dialysis and Renal Disease Management (14 papers) and Vitamin D Research Studies (8 papers). Bastian Dehmel collaborates with scholars based in United States, Germany and United Kingdom. Bastian Dehmel's co-authors include Glenn M. Chertow, William G. Goodman, Geoffrey A. Block, Tilman B. Drüeke, Sharon M. Moe, Patrick S. Parfrey, Kenneth W. Mahaffey, Jürgen Floege, David C. Wheeler and Gérard M. London and has published in prestigious journals such as JAMA, Circulation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Bastian Dehmel

40 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

2010 423 citations Glenn M. Chertow, Botond Csiky et al. Nephrology Dialysis Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bastian Dehmel United States	19	1.3k	486	453	414	273	40	1.8k
Mhairi K. Sigrist Canada	19	1.2k 0.9×	217 0.4×	260 0.6×	149 0.4×	389 1.4×	29	1.9k
Henry Quiñones United States	11	1.1k 0.9×	235 0.5×	172 0.4×	220 0.5×	219 0.8×	14	1.5k
Marie‐Luise Gross Germany	22	793 0.6×	176 0.4×	202 0.4×	182 0.4×	183 0.7×	34	1.3k
Michael Amdahl United States	11	1.0k 0.8×	234 0.5×	207 0.5×	675 1.6×	211 0.8×	14	1.3k
N. El Esper France	17	649 0.5×	178 0.4×	288 0.6×	140 0.3×	197 0.7×	47	1.2k
Elke Magdeleyns Netherlands	18	774 0.6×	1.4k 2.8×	224 0.5×	187 0.5×	165 0.6×	21	2.0k
J. Braun Germany	12	930 0.7×	299 0.6×	240 0.5×	210 0.5×	156 0.6×	29	1.3k
Femke Waanders Netherlands	20	794 0.6×	335 0.7×	280 0.6×	116 0.3×	226 0.8×	47	1.6k
Sydney Benchetrit Israel	18	441 0.3×	144 0.3×	132 0.3×	281 0.7×	158 0.6×	89	1.4k
Irene Capelli Italy	21	466 0.4×	93 0.2×	233 0.5×	121 0.3×	223 0.8×	84	1.1k

Countries citing papers authored by Bastian Dehmel

Since Specialization

Citations

This map shows the geographic impact of Bastian Dehmel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bastian Dehmel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bastian Dehmel more than expected).

Fields of papers citing papers by Bastian Dehmel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bastian Dehmel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bastian Dehmel. The network helps show where Bastian Dehmel may publish in the future.

Co-authorship network of co-authors of Bastian Dehmel

This figure shows the co-authorship network connecting the top 25 collaborators of Bastian Dehmel. A scholar is included among the top collaborators of Bastian Dehmel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bastian Dehmel. Bastian Dehmel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verhulst, Anja, et al.. (2022). Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition. Urolithiasis. 50(2). 119–130. 15 indexed citations

Ariceta, Gema, Laure Collard, Saoussen Abroug, et al.. (2022). ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatric Nephrology. 38(2). 403–415. 13 indexed citations

Sas, David J., Felicity Enders, Tina M. Gunderson, et al.. (2021). Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. Frontiers in Medicine. 8. 592357–592357. 9 indexed citations

Milliner, Dawn S., Pierre Cochat, Sally‐Anne Hulton, et al.. (2021). Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function—data from three placebo-controlled studies. Pediatric Nephrology. 36(7). 1785–1793. 13 indexed citations

Höppe, Bernd, et al.. (2020). Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. Nephrology Dialysis Transplantation. 36(8). 1464–1473. 29 indexed citations

Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2018). A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics. 36(5). 603–612. 7 indexed citations

Warady, Bradley A., Gema Ariceta, Bastian Dehmel, et al.. (2018). A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatric Nephrology. 34(3). 475–486. 21 indexed citations

Briggs, Andrew, Patrick S. Parfrey, Nasreen Khan, et al.. (2016). Analyzing Health-Related Quality of Life in the EVOLVE Trial. Medical Decision Making. 36(8). 965–972. 20 indexed citations

Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2016). Assessing The Cost-Utility of Etelcalcetide: A Markov Model. Value in Health. 19(7). A519–A519. 2 indexed citations

10.

Parfrey, Patrick S., Tilman B. Drüeke, Geoffrey A. Block, et al.. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Queensland's institutional digital repository (The University of Queensland). 5 indexed citations

11.

Chang, Tara I., Safa Abdalla, Gérard M. London, et al.. (2015). The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of Human Hypertension. 30(3). 204–209. 9 indexed citations

12.

Moe, Sharon M., Glenn M. Chertow, Patrick S. Parfrey, et al.. (2015). Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation. 132(1). 27–39. 228 indexed citations

13.

Belozeroff, Vasily, Glenn M. Chertow, Christopher N. Graham, et al.. (2015). Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health. 18(8). 1079–1087. 17 indexed citations

14.

Wheeler, David C., Gérard M. London, Patrick S. Parfrey, et al.. (2014). Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association. 3(6). e001363–e001363. 97 indexed citations

15.

Zitt, Emanuel, Denis Fouque, Stefan H. Jacobson, et al.. (2013). Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clinical Kidney Journal. 6(3). 287–294. 20 indexed citations

16.

Vervloet, Marc, F. Malberti, Neil Ashman, et al.. (2010). “Real-World” use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study. Clinical Nephrology. 74(9). 198–208. 15 indexed citations

17.

Floege, Jürgen, Geoffrey A. Block, Botond Csiky, et al.. (2010). Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation. 25(6). 1916–1923. 34 indexed citations

18.

Böck, A., R. Brunkhorst, Michaël Iskedjian, et al.. (2009). A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. Clinical Kidney Journal. 2(5). 347–353. 16 indexed citations

19.

Mervaala, Eero, Bastian Dehmel, Volkmar Groß, et al.. (1999). Angiotensin-Converting Enzyme Inhibition and AT1 Receptor Blockade Modify the Pressure-Natriuresis Relationship by Additive Mechanisms in Rats with Human Renin and Angiotensinogen Genes. Journal of the American Society of Nephrology. 10(8). 1669–1680. 32 indexed citations

20.

Kratzsch, J., Bastian Dehmel, F Pulzer, et al.. (1997). Increased serum GHBP levels in obese pubertal children and adolescents: relationship to body composition, leptin and indicators of metabolic disturbances. International Journal of Obesity. 21(12). 1130–1136. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact